Event Participants
Executives
1 Fredun Medhora (Managing Director & CFO), Sakhi Panjiyara (Moderator, Kirin Advisors)
Analysts
10 Abhijay (Asia Capital), Ashish Malani (Malani Family Office), Keshav Toshniwal (Kanakala Capital), Kethan Pathak (Individual Investor), Krushi Jain (Share India Securities), Mayur Parekh (VIBAI Capital), Nabeendu Mondal (Individual Investor), Nirali Shah (Ashika Investment Managers), Shreya Bajaj (Serene Alpha Ltd), Vinod Shah (VS Ventures), Yash Gupta (Individual Investor) *Analyst count includes 10 named participants plus 1 unnamed; total 11 lines participated.
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Income (Standalone) | ₹228.25 crores | +90.44% YoY, driven by higher order book, price-related stocking by customers in Q4 FY26 and continued new brand momentum |
| EBITDA | ₹32.78 crores | +92.90% YoY; margin at 14.36%, up 18 bps YoY |
| EBITDA Margin | 14.36% | +18 bps YoY; operating leverage on higher volumes with mix shift toward new age brands |
| Net Profit | ₹13.17 crores | +94.63% YoY; net margin at 5.77%, up 12 bps YoY |
| Net Profit Margin | 5.77% | +12 bps YoY; improvement aided by better gross margin mix |
| Revenue Run Rate | ~₹850 crores | Post-Q1 annualized run rate; FY27 internal target ~₹800 crores, on track to overachieve |
| Working Capital | ~₹170-175 crores | Low for company scale; ~50% held as cash; expected to rise in absolute terms with growth |
| Inventory Days | ~135-140 days | Down ~50% over 2 years; targeting ~120 days within 4 quarters, hovering 110-125 days |
| Credit Rating | BBB+ (upgraded from BBB) | Upgrade contributed to declining interest costs; further improvement expected |
Geographic & Segment Commentary
GX (Generic) Business: Currently present in ~19 states with revenue of ~₹100-110 crores. Management guides 30-35% YoY growth for next 4-5 years given small base and strong market acceptance; product basket expanding with latest molecules and robust supply chain focus. Planned 30-35% growth assumes steady state without major disruptions.
Pet Care: Revenue base of ~₹40-45 crores; targeting 40-50% growth for next 3-4 years. Sub-segments include nutraceuticals, allopathic formulations, functional foods, therapeutics, grooming, and diagnostics. Cat food launch scheduled for Q4 FY27 with planned ₹100 crores revenue within 3-3.5 years of launch; cat biscuit treats (2nd or 3rd entrant in India) in pipeline. Pet care gross margins at 40-55%.
Functional Foods: FY27 revenue target of ₹18-24 crores; 42 variants being added. Snacky branded treats (iron, bone & joint, gut) gaining traction in metro cities; biscuit range performing well in tier 2-4 cities; vet-recommended positioning driving adoption. India's first pet diagnostic center operational in Worli; additional centers in Malad and Vashi.
Manufacturing: Added ~43 manufacturing locations with 5 plants in Palghar; expanding capacities to support new product launches. Goal is to become one of the largest single-location manufacturing units in India by December 2028/early 2029. CapEx of ₹35-45 crores planned annually for next 2 years.
Company-Specific & Strategic Commentary
New Age Brands Portfolio: New age brands (pet care, mobility, nutrition, dermacetics) growing 35-45% YoY, some faster at lower base; vintage business growing 15-20% YoY, resulting in blended 30-35% growth trajectory for next 2 years. Dermacetics gross margin at 70-75%, nutrition 35-50%, mobility 40-50%.
VAGA.in Pet Parenting Platform: Soft launched June 15, 2026; comprehensive pet care e-commerce plus parenting ecosystem (breeders, trainers, groomers, dog walkers, doctors, diagnostics). 1,500-2,000 medicinal products onboarded; all major brands within 20-25 days; beta testing complete within 60-65 days, full campaigns in 90 days. Separate company under Frey Aussie ecosystem.
Organization Structure: Each division has dedicated CEO with 10-25 years industry experience; India's #1 pet nutritionist part of pet care team; low attrition with core team intact for 19 years; R&D team strengthened; positioned for independent division-led execution.
Credit & Financing: Rating upgraded from BBB to BBB+; interest costs declining on improved cash flows, lower limit utilization, and better credit profile. Interest-to-sales ratio drastically reduced; management expects further rating improvement in coming years.
Acquisitions: Small and large acquisition targets in pet care pipeline; management will update investors and markets when finalized; positioned as fundamental to long-term growth strategy.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue (FY27) | Target ~₹800 crores; on track to overachieve | Q1 at ₹228.25 crores implies strong run-rate; management avoids ₹1,000 crore commitment but says optically achievable path exists |
| Blended Growth (next 2 years) | 30-35% YoY | Combination of new age brands (35-45%) and vintage (15-20%); supported by capacity expansion at Palghar and 43 manufacturing locations |
| GX Business Growth (next 4-5 years) | 30-35% YoY | Small base of ₹100-110 crores, market acceptance, huge addressable market as pharma penetration remains low in India |
| Pet Care Growth (next 3-4 years) | 40-50% YoY | Functional foods, cat food launch (Q4 FY27), diagnostics centers, and acquisitions drive growth; OEM opportunities from new plant |
| CapEx (FY27 and FY28) | ₹35-45 crores per year | For capacity expansion and CGMP upgrades; near-term outlay on new plants for functional food capacity |
| EBIT Margin | 12-13% within ~12 quarters | Margin expansion as demographic penetration completes and higher-margin products (dermacetics 70-75% GM) scale; timing is directional not fixed |
| Inventory Days | ~120 days target within 4 quarters | Currently 135-140 days; expected to hover 110-125 days due to 2,100 SKUs and hyper-growth phase in new age products |
| Functional Foods Revenue (FY27) | ₹18-24 crores | Supported by 42 variants, cat biscuits, and expanded distribution |
Risks & Constraints
| Risk | Context |
|---|---|
| Seasonality of Q1 | Historically Q1 is weakest quarter due to customer purchasing patterns in Q4; management expects continued Q1 improvement but cautioned Q4-heavy revenue recognition pattern |
| Margin Expansion Timing | Management explicitly refrained from committing to near-term EBIT margin targets (12-13% guided within 12 quarters, not earlier); expansion-phase sacrifices on margins could persist if penetration goals require |
| Inventory Obsolescence Risk | 2,100 SKUs across multiple brands keep inventory at 135-140 days; though rationalizing, hyper-growth phase may keep inventory elevated; management comfortable within 110-125 day band |
| Competition in Pet Care | Large players present in pet care (~₹1,000 crore+ benchmark); management sees opportunity in under-penetrated market but competitive intensity could pressure margins in new categories like cat food |
| Raw Material Price Volatility | Q1 growth partially driven by advance booking of orders at favorable prices during Q4 FY26 raw material price fluctuations; sustainability of such boost not guaranteed in future quarters |
| Growth Execution Risk | 30-35%+ multi-year growth targets depend on capacity expansion (December 2028 single-location plant target), new product launches, and geographic expansion; any delays could impact delivery |
Q&A Highlights
Multi-Year Growth Outlook
- Question: Where can Fredun be in 3-5 years given Q1 revenue nearly equals FY23 full-year revenue? (Vinod Shah, VS Ventures)
- Answer: Two-part growth story: New age brands growing 35-45% YoY, vintage business 15-20%; blended 30-35% for next 2 years. Capacity expansions at own facility and 5 Palghar plants plus 43 new manufacturing locations will add product lines over 3-5 years. (Fredun Medhora)
GX Business Opportunity
- Question: How large can domestic GX opportunity become over next 2-3 years given presence across 17-19 states? (Mayur Parekh, VIBAI Capital)
- Answer: GX at ~₹100-110 crores is very small base; company operating in ~19 states. Pharmacy distribution confidence high due to broad therapeutic range; 30-35% YoY growth anticipated for next 4-5 years. India's pharma penetration still poor—1% of population coming out of poverty equals European-sized market. (Fredun Medhora)
VAGA.in Platform
- Question: What developments are happening with VAGA.in website? (Keshav Toshniwal, Kanakala Capital)
- Answer: Team built over 3-4 months; all major brands onboarded within 20-25 days; 1,500-2,000 medicinal products across companies. Soft launched June 15; beta testing for 60-65 days; campaigns in 90 days. Platform is pet parenting ecosystem—breeders, trainers, groomers, dog walkers, doctors, diagnostics, and pet blood donation portal. 24/7 helpline planned. (Fredun Medhora)
Q1 Growth Drivers and Seasonality
- Question: Q1 historically weaker than Q4; what drove exponential Q1 increase and can it sustain? (Nabeendu Mondal, individual investor)
- Answer: Q1 always optically weaker due to Q4 purchase/inventory patterns; but Q1 has improved YoY for many years. This year received boost from price fluctuation—company carried higher stock and booked orders at old prices, offering customers lower price increases; "slight boost" from this. Coming quarters should show similar growth levels. Company's highest growth was 110-115% YoY in 2008-09 though smaller base. (Fredun Medhora)
Functional Foods
- Question: How is functional foods division performing, particularly Jain food? (Nabeendu Mondal)
- Answer: Functional foods part of pet care; 42 variants being added. Chain variant performing well in certain pockets; metro response strong. Normal biscuit range doing well in tier 2-4 cities. Vet-recommended treats (snacky iron, bone & joint, gut) gaining traction; cat biscuits launching (likely 2nd/3rd in India); cat functional line within 6-7 months. Focus on product acceptance over dumping sales; small wins from customer loyalty more valuable than numbers. (Fredun Medhora)
Working Capital
- Question: Can you elaborate on working capital this quarter and next 2 years? (Krushi Jain, Share India Securities)
- Answer: Run rate ~₹850 crores with working capital of ~₹170-175 crores—not high for company size; ~50% of working capital in cash. Absolute working capital will increase at ₹2,000-3,000 crore revenue but in line with manufacturing industry norms. Positive cash flows, higher margins, and repeat customer acquisition cost reduction should improve gross/net margins tremendously. (Fredun Medhora)
Interest Costs and Inventory Days
- Question: Has interest rate environment changed meaningfully—QoQ interest cost down despite YoY sales growth? Also, inventory days targeting? (Ashish Malani, Malani Family Office)
- Answer: Interest costs declining due to better cash flows, reduced limit utilization, and credit rating upgrade from BBB to BBB+. Interest-to-sales drastically reduced; however, temporary spending acceptable for market entry. Inventory days down ~50% over 2 years; targeting ~120 days within 4 quarters, hovering 110-125 days due to 2,100 SKUs and hyper-growth phase. (Fredun Medhora)
Revenue and EBIT Targets
- Question: Can we target ₹1,000 crores revenue and ₹100 crores EBIT this year? And EBIT margins to 12-13% in 15-18 months? (Kethan Pathak, individual investor)
- Answer: Management explicitly declined to commit to ₹1,000 crores; guided target was ~₹800 crores for FY27 and on track to overachieve. EBIT margin improvement: could reach 12-13% within next 12 quarters ("comfortably near that number"); not pinning to specific quarter—90-day reporting cycle doesn't match business cycle. Company focused on industry impact over profit trajectory; "not even 1% of where we want to be as a company." (Fredun Medhora)
Pet Care Revenue Scaling
- Question: Pet care generating ₹40-43 crores; what scale and margins over 3-5 years? (Yash Gupta, individual investor)
- Answer: Pet care unique—only company with nutraceuticals, allopathic formulations, functional foods, therapeutics, grooming, diagnostics. India's first diagnostic center in Worli; another in Malad; third in Vashi. Cat food launching Q4 FY27, planned ₹100 crores revenue within 3-3.5 years. Plant being built for functional food capacity plus OEM for others. Expecting 40-50% growth next 3-4 years; potential spurt from cat food and diagnostics; small acquisitions in pipeline. (Fredun Medhora)
Organization Structure
- Question: Any formal structure/execution team being put in place for independent division CEOs? (Abhijay, Asia Capital)
- Answer: Every division/unit business already has dedicated CEO with 10-25 years experience; India's #1 pet nutritionist on team; nutrition and CAD teams are industry stalwarts with MNC launch experience. Strong R&D and operations teams; one of the lowest attrition rates—core team hired 19 years ago all still present. Management structure forming as natural process; will be better organized in 5-7 years. (Fredun Medhora)
Key Takeaway
Fredun Pharmaceuticals delivered a remarkable Q1 FY27 with standalone total income of ₹228.25 crores (+90.44% YoY), EBITDA of ₹32.78 crores (+92.90%; margin 14.36%), and net profit of ₹13.17 crores (+94.63%; margin 5.77%), aided by advance order books from favorable pricing during Q4 FY26 raw material fluctuations. The growth engine remains a diversified portfolio—new age brands (pet care, mobility, nutrition, dermacetics) growing 35-45% YoY alongside a 15-20% vintage business, with blended 30-35% growth guided for the next 2 years. The company is executing on multiple fronts: VAGA.in pet parenting platform soft-launched with full rollout in 90 days, cat food entering Q4 FY27, three pet diagnostic centers opening, and ₹35-45 crores annual CapEx toward becoming a top single-location manufacturer by December 2028. Management guided FY27 revenue of ~₹800 crores (on track to overachieve), targeting EBIT margins of 12-13% within 12 quarters, with working capital at ₹170-175 crores and inventory rationalizing toward 120 days. Key watch points include seasonality dynamics favoring Q4, sustainability of price-driven order boosts, and execution of the pet care growth roadmap through acquisitions and new-product launches.